Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Collecting Duct-Targeted Lipid Nanoparticles Deliver <i>Pkd2</i> mRNA to Restore Polycystin-2 and Attenuate ADPKD.

bioRxiv : the preprint server for biology·2026
Same author

Investigation of Urinary Extracellular Vesicles as Novel and Safe Therapeutics for Autosomal Recessive Polycystic Kidney Disease (ARPKD).

Journal of biomedical materials research. Part A·2026
Same author

Bioengineering and nephrology converge to drive kidney-targeted therapies.

Nature reviews. Nephrology·2025
Same author

Nucleosome placement and polymer mechanics explain genomic contacts on 100 kb scales.

Nucleic acids research·2025
Same author

Genetically engineering cells to produce therapeutically boosted extracellular vesicles for cardiovascular calcification.

Biomaterials·2025
Same author

Bacteria detect neutrophils via a system that responds to hypochlorous acid and flow.

bioRxiv : the preprint server for biology·2025
Same journal

Shape factor analysis as a quantitative framework for assessing spheroid and organoid morphology and invasiveness.

APL bioengineering·2026
Same journal

HB-EGF enhances collective cell migration via spatial coordination of traction.

APL bioengineering·2026
Same journal

A pump-free microfluidic device for integrated multi-functional testing of tumor spheroids.

APL bioengineering·2026
Same journal

Photobiomodulation outperforms ultrasound in reducing IL-1 <b><i>β</i></b> -driven chondrocyte inflammation.

APL bioengineering·2026
Same journal

Research progress of 3D-printed anti-infective bone tissue engineering scaffolds based on triply periodic minimal surface structures.

APL bioengineering·2026
Same journal

Biomolecular and cellular chirality: Novel diagnostic perspectives for diseases.

APL bioengineering·2026
See all related articles

Related Experiment Video

Updated: Jul 26, 2025

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
11:17

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Published on: June 13, 2019

7.4K

Targeting the ADPKD methylome using nanoparticle-mediated combination therapy.

Annie Trinh, Yi Huang1, Hanjuan Shao

  • 1Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.

APL Bioengineering
|June 12, 2023
PubMed
Summary
This summary is machine-generated.

Combining DNA methylation inhibitors (DNMTi) with ADPKD drugs like metformin and tolvaptan synergistically reduces cyst growth. This combination therapy restores normal DNA methylation patterns, targeting ADPKD-associated genes for potential therapeutic benefits.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.0K

Related Experiment Videos

Last Updated: Jul 26, 2025

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
11:17

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Published on: June 13, 2019

7.4K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.0K

Area of Science:

  • Nephrology
  • Epigenetics
  • Pharmacology

Background:

  • Autosomal dominant polycystic kidney disease (ADPKD) exhibits DNA methylation aberrancies, indicating the methylome as a therapeutic target.
  • The combined effect of DNA methylation inhibitors (DNMTi) and ADPKD drugs on disease methylation patterns remains underexplored.

Purpose of the Study:

  • To investigate the synergistic effects of DNMTi (5-aza-2'-deoxycytidine, Aza) combined with ADPKD drugs (metformin and tolvaptan, MT) on ADPKD cells.
  • To analyze the impact of this combination therapy on disease-associated methylation patterns.

Main Methods:

  • PKD1-Het cells were treated with Aza and MT, delivered as free drugs or nanoparticles.
  • Reduced representation bisulfite sequencing (RRBS) was employed to analyze global and site-specific methylation patterns.
  • Cell viability and cystic growth were assessed.

Main Results:

  • Aza synergized with MT to significantly reduce cell viability and cystic growth in ADPKD models.
  • The combination therapy restored a bimodal methylation landscape, similar to somatic cells, contrasting with Aza alone.
  • Site-specific hypomethylation was observed at ADPKD-associated genes and novel cancer-associated genes implicated in ADPKD pathogenesis.

Conclusions:

  • Combination therapy with DNMTi and ADPKD drugs demonstrates synergistic effects in reducing ADPKD cell viability and cyst growth.
  • This approach modulates DNA methylation patterns, offering a promising therapeutic strategy by targeting key disease-associated genes.
  • Further research is warranted to explore the underlying regulatory mechanisms and translate these findings to in vivo applications.